Decades after breakthrough, scientists still puzzling over mRNA delivery

Nicole DeFeudis

Editor

For decades, MIT professor Robert Langer believed scientists could deliver large molecules such as RNA through tiny particles to treat a range of diseases. When …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Decades after breakthrough, scientists still puzzling over mRNA delivery

Nicole DeFeudis

Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Decades af­ter break­through, sci­en­tists still puz­zling over mR­NA de­liv­ery

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Decades after breakthrough, scientists still puzzling over mRNA delivery

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CMS explains what went into its first round of drug price negotiations

Immunology biotech Inmagene to join Nasdaq through reverse merger with what's left of Ikena

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings